By otakuyassine3@gmail.com 
Blair William & Co. IL increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 42.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,742 shares of the medical research company’s stock after purchasing an additional 1,699 shares during the quarter. Blair William & Co. IL’s holdings in IQVIA were worth $1,128,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of IQV. Pine Valley Investments Ltd Liability Co boosted its position in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares in the last quarter. Howard Capital Management Inc. boosted its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after purchasing an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after buying an additional 56 shares in the last quarter. Cypress Wealth Services LLC lifted its position in shares of IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock worth $244,000 after buying an additional 57 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its stake in IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock valued at $253,000 after buying an additional 58 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on IQV shares. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $249.05.
Get Our Latest Research Report on IQV
IQVIA Stock Up 1.9 %
Shares of NYSE:IQV opened at $174.52 on Thursday. IQVIA Holdings Inc. has a 1 year low of $169.11 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business’s 50-day moving average is $191.43 and its 200-day moving average is $204.92. The company has a market capitalization of $30.77 billion, a price-to-earnings ratio of 23.27, a P/E/G ratio of 1.99 and a beta of 1.50.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.